---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-025532"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T14:49:30.077633+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enanta reports Q4 net loss $26.3M, revenue $20.3M; initiates Phase 2 COVID-19 trial

## Summary
- Q4 royalty revenue $20.3M (down 14% YoY); full year revenue $86.2M vs $97.1M.
- Q4 net loss $26.3M ($1.27 loss per share) vs $24.6M loss ($1.22) prior year.
- Cash $278.5M; expects runway into Q4 fiscal 2024.
- Initiated Phase 2 SPRINT trial of oral 3CL protease inhibitor EDP-235 for mild/moderate COVID-19.
- FY2023 guidance: R&D $210-230M, G&A $46-52M.

## SEC filing metadata
- accession: 0000950170-22-025532
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/0000950170-22-025532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/enta-20221121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-025532
- JSON: https://secwatch.observer/filing/0000950170-22-025532.json
- Plain text: https://secwatch.observer/filing/0000950170-22-025532.txt

## Key facts
- Earnings Releases
  ENANTA PHARMACEUTICALS INC reported twelve months ended September 30, 2022 results: revenue $86.2 million, net income Net loss was $121.8 million, EPS loss of $5.91 per diluted common share. Guidance initiated.
  - Period: twelve months ended September 30, 2022
  - Revenue: $86.2 million
  - Net income: Net loss was $121.8 million
  - EPS: loss of $5.91 per diluted common share
  - Guidance: initiated
  - Result: reported results
  source text: For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021. Research and development expenses were $34.8 million for the three months ended September 30, 2022, compared to $48.9 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021. The decreases in both periods were due to the timing and scope of the company’s clinical trials. General and administrative expenses totaled $12.6 million for the three months ended September 30, 2022, compared to $8.4 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, general and administrative expenses were $45.5 million compared to $32.5 million in 2021. The increases in both periods were due primarily to additional headcount and stock compensation expense. Enanta recorded an income tax expense
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/0000950170-22-025532-index.htm
- Earnings Releases
  ENANTA PHARMACEUTICALS INC reported three months ended September 30, 2022 results: revenue $20.3 million, net income Net loss was $26.3 million, EPS loss of $1.27 per diluted common share. Guidance initiated.
  - Period: three months ended September 30, 2022
  - Revenue: $20.3 million
  - Net income: Net loss was $26.3 million
  - EPS: loss of $1.27 per diluted common share
  - Guidance: initiated
  - Result: reported results
  source text: Total revenue of $20.3 million for the three months ended September 30, 2022, consisted of royalty revenue derived from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET®, compared to royalty revenue of $23.6 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021. Research and development expenses were $34.8 million for the three months ended September 30, 2022, compared to $48.9 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021. The decreases in both periods were due to the timing and scope of the company’s clinical trials. General and administrative expenses totaled $12.6 million for the three months ended September 30, 2022, compared to $8.4 million for the three months ended Septe
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/0000950170-22-025532-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.